Guinea-Bissau vs Haiti: Average cost of multi drug-resistant tuberculosis treatment
Guinea-Bissau
1,120 constant 2022 US$
in 2024
Haiti
1,098 constant 2022 US$
in 2024
Guinea-Bissau rank
43rd
Haiti rank
44th
Average cost of multi drug-resistant tuberculosis treatment over time
- Guinea-Bissau
- Haiti
How they compare
Guinea-Bissau currently reports 1,120 constant 2022 US$ against 1,098 constant 2022 US$ in Haiti, a difference of 22 constant 2022 US$.
The two have swapped places 6 times across 8 shared years of data; in 2017 it was Guinea-Bissau ahead.
Guinea-Bissau ranks 43rd and Haiti ranks 44th of 92 countries.
Across the 2 decades both report, Guinea-Bissau averaged higher in 1 and Haiti in 1.
Head to head by decade
| Decade | Guinea-Bissau | Haiti | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 2,481 constant 2022 US$ | 1,248 constant 2022 US$ | 1,234 constant 2022 US$ | Guinea-Bissau |
| 2020s | 1,045 constant 2022 US$ | 3,048 constant 2022 US$ | 2,003 constant 2022 US$ | Haiti |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, Guinea-Bissau or Haiti?
- Guinea-Bissau, at 1,120 constant 2022 US$ against 1,098 constant 2022 US$ in Haiti as of 2024.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between Guinea-Bissau and Haiti?
- 22 constant 2022 US$, with Guinea-Bissau ahead.
- How many years of comparable data are there for Guinea-Bissau and Haiti?
- 8 years are reported by both, from 2017 to 2024.
- How do Guinea-Bissau and Haiti rank globally for average cost of multi drug-resistant tuberculosis treatment?
- Guinea-Bissau ranks 43rd and Haiti ranks 44th of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.